Over-the-Counter Medicines
Eldoral Tab.
- Product Category
- Antitussive expectorant
- Active Ingredients
- Erdostein
- Appearance
- White rectangular film-coated tablet
- Reimbursement Code
- 648101580
01 / 02
1. Ingredient content
1 tablet
- Active ingredient: Erdostein (in-house specification) ································································································································································ in 300mg
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, sodium starch glycolate, carnauba lead, colloidal silicon dioxide, povidone, polyethylene glycol 6000, hypromellose 2910
2. Effectiveness
Mucolysis and expectoration in acute and chronic respiratory diseases
3. Dosage and dosage
Adults: As erdosteine, take 300 mg orally 2-3 times a day.
When administering for acute respiratory disease, do not administer for more than 10 consecutive days.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Patients with liver cirrhosis and patients with cystathionine-synthase deficiency (metabolites of this drug may interfere with methionine metabolism).
3) Peptic ulcer patients
4) Patients with severe renal impairment (creatinine clearance <25 mL/min)
5) Patients with severe liver impairment
2. Administer with caution to the following patients.
Patients with mild (mild symptoms) and moderate hepatic impairment (No increase in adverse reactions due to this drug was observed, but the dose of this drug should not exceed 300 mg per day.)
3. Adverse reactions
1) Overdosage (more than 1200 mg per day) may cause sweating, dizziness, and flushing.
2) Nervous system: headache
3) Respiratory system: cold, difficulty breathing
4) Digestive system: abnormal taste, nausea, vomiting, diarrhea, epigastric pain, abdominal pain (hunger), heartburn
5) Skin: Hives, erythema (red spots), eczema
6) Domestic post-marketing surveillance results (Number of investigated cases: 3,303 for capsules, 791 for syrups) The adverse reactions reported are as follows, and it is unclear whether they are related to this drug. : Fatigue, indigestion,
Abdominal pain (hunger), gastrointestinal disorder, diarrhea, vomiting, headache, sores, erythema nodosum (red spots on protruding areas), palpitations (palpitations), facial edema, whole body edema, itching, lethargy, dazedness,
rash
4. Interaction
Particular caution should be exercised when using expectorants (phlegm medicines) in combination with cough medicine, as they may increase the risk of bronchial infection due to difficulties in expelling phlegm from the bronchial tubes due to cough relief and may cause bronchospasm (constriction and relaxation of the bronchi).
5. Administration to pregnant and lactating women
In animal experiments, no direct or indirect toxicity was found with respect to conception (pregnancy), embryonic development of the fetus, or postpartum (postpartum) development. However, since the safety of administration during pregnancy or lactation has not been established, it is advisable not to administer to pregnant women, women who may be pregnant, or lactating women.
6. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Erdostein (in-house specification) ································································································································································ in 300mg
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, sodium starch glycolate, carnauba lead, colloidal silicon dioxide, povidone, polyethylene glycol 6000, hypromellose 2910
2. Effectiveness
Mucolysis and expectoration in acute and chronic respiratory diseases
3. Dosage and dosage
Adults: As erdosteine, take 300 mg orally 2-3 times a day.
When administering for acute respiratory disease, do not administer for more than 10 consecutive days.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Patients with liver cirrhosis and patients with cystathionine-synthase deficiency (metabolites of this drug may interfere with methionine metabolism).
3) Peptic ulcer patients
4) Patients with severe renal impairment (creatinine clearance <25 mL/min)
5) Patients with severe liver impairment
2. Administer with caution to the following patients.
Patients with mild (mild symptoms) and moderate hepatic impairment (No increase in adverse reactions due to this drug was observed, but the dose of this drug should not exceed 300 mg per day.)
3. Adverse reactions
1) Overdosage (more than 1200 mg per day) may cause sweating, dizziness, and flushing.
2) Nervous system: headache
3) Respiratory system: cold, difficulty breathing
4) Digestive system: abnormal taste, nausea, vomiting, diarrhea, epigastric pain, abdominal pain (hunger), heartburn
5) Skin: Hives, erythema (red spots), eczema
6) Domestic post-marketing surveillance results (Number of investigated cases: 3,303 for capsules, 791 for syrups) The adverse reactions reported are as follows, and it is unclear whether they are related to this drug. : Fatigue, indigestion,
Abdominal pain (hunger), gastrointestinal disorder, diarrhea, vomiting, headache, sores, erythema nodosum (red spots on protruding areas), palpitations (palpitations), facial edema, whole body edema, itching, lethargy, dazedness,
rash
4. Interaction
Particular caution should be exercised when using expectorants (phlegm medicines) in combination with cough medicine, as they may increase the risk of bronchial infection due to difficulties in expelling phlegm from the bronchial tubes due to cough relief and may cause bronchospasm (constriction and relaxation of the bronchi).
5. Administration to pregnant and lactating women
In animal experiments, no direct or indirect toxicity was found with respect to conception (pregnancy), embryonic development of the fetus, or postpartum (postpartum) development. However, since the safety of administration during pregnancy or lactation has not been established, it is advisable not to administer to pregnant women, women who may be pregnant, or lactating women.
6. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture